Right, this will invariably happen. 

Few interesting reasons why this might be falsely suppressing the price:

1. Generic Liraglutide will guarantee customer GLP-1 access
2. 503b compounding interpretation opens up the possibility of continuing semaglutide compounding

The stock is heavily shorted (24%), I believe shorts are present for the volatility given the impending announcement regarding semaglutide. 
Shorts will exit with the news (it would be stupid not to given the above stated reasons). 

This will cause a short squeeze forcing the price to climb closer to intrinsic value (~$40-50/share)

$HIMS